Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
about
Managing breast cancer in younger women: challenges and solutionsThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsReply to F. Tomao et al.Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventionsAdjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer SkillsAbsolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant settingAdjuvant ovarian function suppression and cognitive function in women with breast cancer.Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients.The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case.Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.News on the medical treatment of young women with early-stage HER2-negative breast cancer.A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress.The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al.Are we ready to change clinical practice after the 'soft and text' results?Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation.Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Long-term consequences of ovarian ablation for premenopausal breast cancer.Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
P2860
Q26771184-129BEDAA-587B-4EE3-A333-956CF63649F8Q26782449-1DF66369-52F3-4DFD-98F1-D43BE533CCAFQ33816570-0AC0892E-9FA2-49C0-A4F0-4BEA948D1E95Q36413980-37604D05-2922-40DE-A6D2-77CF00F44EB5Q36818466-547A9833-ED17-4714-9D49-458EDD321B95Q36915190-6865AF55-BE5B-4318-9266-F9D0AFB35DC0Q36917641-4AA0DD18-C454-4A09-A5CD-46E3B28F74FCQ37130142-9AD03698-942A-4678-8F7E-58E5C3A27D70Q37174823-694DD665-4FDF-486B-A34C-EAE63A6EA03FQ37175081-53EB8F38-8315-4F08-9CA8-08699F10BDB0Q37316811-1771B4A7-6DD7-4091-8046-2974B82ACA78Q37341647-885A2041-477A-4408-894D-528F0EFDF4C0Q37425427-3E8901FD-2A61-43BE-8A7A-64E31ECAAA1EQ38658655-A8B38222-2EAF-410F-A635-7BB221B3FEE5Q38870541-02EDBD34-2540-4AE2-A4F5-6EA0D9DDCFE3Q38947105-9B0E1342-6207-478E-865E-0C68F7996835Q38968531-75A1060A-D78F-4170-87A9-CDCB05D992A5Q39260461-EEB89CD6-21B1-42E1-9940-F5EFF4756BB8Q39375196-D28E94FA-512B-41B5-90F0-00294B6FAE3FQ39405358-8A421298-0161-4027-ACF5-9A5C114E0D23Q41594757-8E9927F8-58D4-4D1F-BEA0-6C33EB1E5EB3Q42356573-545D05E8-4634-418E-B7F9-9BB952737D9AQ47097531-1B1578F2-EE2A-42EB-9B19-ED60756E3457Q48124124-F59A3FF3-4AFD-4D2C-ADC0-F4A726E6E317Q48376613-2CFD1F15-D53C-4C01-8377-E1924E8016CFQ48507477-4A0B13EC-F863-4637-89C8-5750A2611958Q49608951-259862BD-3151-49C4-83A9-575C03E49D09Q50848449-54AED3DF-F77C-4E63-B7C1-2D98F405C83DQ54974390-D97D2BD3-A36D-481A-9D12-26014E46D6FFQ54976962-87F0C0BA-381B-4108-843A-26C6E7A2A013Q55090991-EF3771DB-9C4C-4236-B211-88D3556B7900
P2860
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Patient-reported outcomes with ...... two phase 3 randomised trials.
@ast
Patient-reported outcomes with ...... two phase 3 randomised trials.
@en
type
label
Patient-reported outcomes with ...... two phase 3 randomised trials.
@ast
Patient-reported outcomes with ...... two phase 3 randomised trials.
@en
prefLabel
Patient-reported outcomes with ...... two phase 3 randomised trials.
@ast
Patient-reported outcomes with ...... two phase 3 randomised trials.
@en
P2093
P2860
P50
P1433
P1476
Patient-reported outcomes with ...... two phase 3 randomised trials
@en
P2093
Alan S Coates
Aron Goldhirsch
Barbara A Walley
Carlo Tondini
Gini F Fleming
Graziella Pinotti
Harold J Burstein
Jürg Bernhard
Karen N Price
Karin Ribi
P2860
P304
P356
10.1016/S1470-2045(15)00049-2
P577
2015-06-16T00:00:00Z